Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Viruses ; 14(10)2022 09 29.
Artigo em Inglês | MEDLINE | ID: mdl-36298704

RESUMO

Coronavirus disease 19 (COVID-19) is caused by viral infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Where upregulation of several important biomarkers and multiple organ dysfunction occurs, this study aimed to evaluate the association of cardiac biomarkers and CS induced acute lung damage with disease severity and mortality in survival of COVID-19 patients. A total of 500 COVID-19 patients with elevated cardiac biomarkers were studied for the analysis of myocardial abnormality through cardiac enzymes, inflammatory biomarkers, and the expression analysis of various cytokines, including IL-1, IL-6, IL-10, IL-17, and IL-25 genes. The elevation of various cardiac enzymes including LDH (87%), CK (78.4%), TNI (80.4%), CK-MB (83%), and D-dimer (80.8%) were found correlated (p < 0.001) with COVID-19 infection. Cardiac enzyme elevation was highly associated with an increased level of inflammatory biomarkers such as CRP (14.2%), SAA (11.4%) and erythrocyte sedimentation rate (ESR) (7.8%) (p = 0.001 for all). The quantitative expression analysis of IL-10, 1L-17, and 1L-25 were found to be high, while those of IL-1 and IL-6 were moderately elevated. The death-to-live ratio of COVID-19 patients was 457:43 indicating that the patients having elevated levels of both CKMB, D-dimer, CK and IL-1, IL-6, IL-10 and D-dimer, Troponin, CK and IL-1, IL-10 had high fatality rate (73% and 12% respectively). The current finding concludes that the evaluation of cardiac biomarkers with cytokine storm plays a significant role in COVID-19-associated anatomical organ damage, myocardial injury, and mortality. Physicians should pay special attention to cardiac biomarkers in patients with old age, inflammation, and comorbidities among COVID-19 infections.


Assuntos
COVID-19 , Humanos , SARS-CoV-2 , Interleucina-6 , Interleucina-10 , Interleucina-17/genética , Paquistão , Biomarcadores , Citocinas , Troponina , Interleucina-1
2.
Biomed Pharmacother ; 133: 110947, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33197765

RESUMO

In December 2019, a pneumonia outbreak of unknown etiology was reported which caused panic in Wuhan city of central China, which was later identified as Coronavirus disease (COVID-19) caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by the Chinese Centre for Disease Control and Prevention (CDC) and WHO. To date, the SARS-CoV-2 spread has already become a global pandemic with a considerable death toll. The associated symptoms of the COVID-19 infection varied with increased inflammation as an everyday pathological basis. Among various other symptoms such as fever, cough, lethargy, gastrointestinal (GI) symptoms included diarrhea and IBD with colitis, have been reported. Currently, there is no sole cure for COVID-19, and researchers are actively engaged to search out appropriate treatment and develop a vaccine for its prevention. Antiviral for controlling viral load and corticosteroid therapy for reducing inflammation seems to be inadequate to control the fatality rate. Based on the available related literature, which documented GI symptoms with diarrhea, inflammatory bowel diseases (IBD) with colitis, and increased deaths in the intensive care unit (ICU), conclude that dysbiosis occurs during SARS-COV-2 infection as the gut-lung axis cannot be ignored. As probiotics play a therapeutic role for GI, IBD, colitis, and even in viral infection. So, we assume that the inclusion of studies to investigate gut microbiome and subsequent therapies such as probiotics might help decrease the inflammatory response of viral pathogenesis and respiratory symptoms by strengthening the host immune system, amelioration of gut microbiome, and improvement of gut barrier function.


Assuntos
COVID-19/microbiologia , Disbiose , Microbioma Gastrointestinal , Probióticos , Humanos , SARS-CoV-2
3.
J Pak Med Assoc ; 69(10): 1543-1546, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31622313

RESUMO

In the current study the occurrence and severity of iron deficiency anemia (IDA) was recorded from September, 2014 to April, 2015 in children of school age in District Tank. Random sampling of blood and questionnaires were planned to record general information while blood was analyzed through automatic haematological analyzer model Sysmex Kx- 21 Stromatolyser- WH, Cell Pack (Merck). Total prevalence of anaemia in school age children was 37.1% with 63.8% in boys and 64.3% in girls.


Assuntos
Anemia Ferropriva/epidemiologia , Anemia Ferropriva/metabolismo , Criança , Pré-Escolar , Fadiga/epidemiologia , Feminino , Hemoglobinas/metabolismo , Humanos , Masculino , Debilidade Muscular/epidemiologia , Paquistão/epidemiologia , Prevalência , Índice de Gravidade de Doença , Classe Social
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA